Synapse-associated protein 90/postsynaptic density-95-associated protein (SAPAP) is expressed differentially in phencyclidine-treated rats and is increased in the nucleus accumbens of patients with schizophrenia

被引:28
作者
Kajimoto, Y
Shirakawa, O
Lin, XH
Hashimoto, T
Kitamura, N
Murakami, N
Takumi, T
Maeda, K
机构
[1] Kobe Univ, Grad Sch Med, Dept Environm Hlth & Safety, Div Psychiat & Neurol,Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Kobe Gen City Hosp, Dept Psychiat & Neurol, Kobe, Hyogo, Japan
[3] Labour Welf Corp, Kobe Rosai Hosp, Dept Psychiat, Kobe, Hyogo, Japan
[4] Osaka Biosci Inst, Dept Neurosci, Osaka, Japan
关键词
phencyclidine (PCP); differential display; glutamate; NMDA; schizophrenia; brain;
D O I
10.1038/sj.npp.1300212
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Phencyclidine (PCP) induces a psychotomimetic state that closely resembles schizophrenia. Therefore, PCP-treated animals can provide a model for schizophrenia. Using differential display, we identified a gene regulated by the delayed action of PCP in rat nucleus accumbens (NAcs). Sequence analysis showed that the cDNA clone obtained was identical to rat synapse-associated protein 90/ postsynaptic density-95-associated protein 1 (SAPAP1). Quantitative reverse transcriptase (RT)-PCR analysis showed that SAPAP1 mRNA had increased significantly in rat NAc (P<0.0001) and hippocampus (P<0.01) 24 h after a PCP (10 mg/kg) injection as compared to the controls. Immunoquantification using an anti-SAPAP1 antibody indicated that immunoreactivity for SAPAP1 increased significantly (P<0.05) in the NAcs of unmedicated patients with schizophrenia, as compared to the control subjects and medicated patients with schizophrenia. Our findings support the hypothesis that there is abnormal glutamatergic neurotransmission in schizophrenia and show evidence of abnormalities in the intracellular signal transduction via N-methyl-D-aspartate (NMDA) receptors.
引用
收藏
页码:1831 / 1839
页数:9
相关论文
共 60 条
[1]   Are schizophrenic and bipolar disorders related? A review of family and molecular studies [J].
Berrettini, WH .
BIOLOGICAL PSYCHIATRY, 2000, 48 (06) :531-538
[2]   CHROMOSOME-18 DNA MARKERS AND MANIC-DEPRESSIVE ILLNESS - EVIDENCE FOR A SUSCEPTIBILITY GENE [J].
BERRETTINI, WH ;
FERRARO, TN ;
GOLDIN, LR ;
WEEKS, DE ;
DETERAWADLEIGH, S ;
NURNBERGER, JI ;
GERSHON, ES .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) :5918-5921
[3]   D-CYCLOSERINE ADJUVANT THERAPY TO CONVENTIONAL NEUROLEPTIC TREATMENT IN SCHIZOPHRENIA - AN OPEN-LABEL STUDY [J].
CASCELLA, NG ;
MACCIARDI, F ;
CAVALLINI, C ;
SMERALDI, E .
JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1994, 95 (02) :105-111
[4]   A neurobiological basis for substance abuse comorbidity in schizophrenia [J].
Chambers, RA ;
Krystal, JH ;
Self, DW .
BIOLOGICAL PSYCHIATRY, 2001, 50 (02) :71-83
[5]   PDZ proteins organize synaptic signaling pathways [J].
Craven, SE ;
Bredt, DS .
CELL, 1998, 93 (04) :495-498
[6]   A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2 [J].
Detera-Wadleigh, SD ;
Badner, JA ;
Berrettini, WH ;
Yoshikawa, T ;
Goldin, LR ;
Turner, G ;
Rollins, DY ;
Moses, T ;
Sanders, AR ;
Karkera, JD ;
Esterling, LE ;
Zeng, J ;
Ferraro, TN ;
Guroff, JJ ;
Kazuba, D ;
Maxwell, ME ;
Nurnberger, JI ;
Gershon, ES .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5604-5609
[7]   N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia [J].
Dracheva, S ;
Marras, SAE ;
Elhakem, SL ;
Kramer, FR ;
Davis, KL ;
Haroutunian, V .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (09) :1400-1410
[8]  
GAO XM, 1993, EUR J PHARMACOL, V241, P7
[9]  
Gao XM, 1996, SYNAPSE, V23, P274, DOI 10.1002/(SICI)1098-2396(199608)23:4<274::AID-SYN5>3.0.CO
[10]  
2-4